Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
atisnolerbart
- Development stage
- Phase 3
- Lead developer
- Regeneron Pharmaceuticals
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
Atisnolerbart is a **human monoclonal IgG4 antibody** targeting **Bet v 1**, the major birch pollen allergen. It is part of a clinical mixture of three monoclonal antibodies (atisnolerbart, bremzalerbart, umesolerbart), developed for the treatment of seasonal allergic diseases, particularly **allergic rhinitis and conjunctivitis** caused by birch pollen. The antibody binds specifically to Bet v 1, neutralizing its ability to trigger allergic immune responses. Atisnolerbart (REGN5715) is developed using fully human mAb sequences and is currently in phase 3 clinical trials for these indications[1][3][5].
- Other names
- REGN5715REGN-5715REGN 5715
02
Targets
Bet v 1
Beyond the preview
Go deeper on atisnolerbart.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on atisnolerbart.